CD38 and immune system disorder: There were indications that subjects treated for longer had lower levels of 2-LTR circular HIV-1 DNA and residual plasma HIV-1 RNA, accompanied by a reduction in the frequency of CD4+CD38+ and CD8+CD38+ cells, together suggesting that control of virus replication and resolution of immune dysfunction improve with longer duration of therapy.